Cyanocobalamin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00115 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 37 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | biotin metabolic disease | KG + DL |
| 2 | inborn error of biotin metabolism | KG + DL |
| 3 | non-syndromic esophageal malformation | KG + DL |
| 4 | inflammatory myopathy with abundant macrophages | KG + DL |
| 5 | idiopathic eosinophilic myositis | KG + DL |
| 6 | immune-mediated necrotizing myopathy | KG + DL |
| 7 | antisynthetase syndrome | KG + DL |
| 8 | proteinuria | KG + DL |
| 9 | focal myositis | KG + DL |
| 10 | primary CD59 deficiency | KG + DL |
| 11 | neonatal autoimmune hemolytic anemia | KG + DL |
| 12 | primary release disorder of platelets | KG + DL |
| 13 | mixed-type autoimmune hemolytic anemia | KG + DL |
| 14 | pseudo-von Willebrand disease | KG + DL |
| 15 | drug-induced autoimmune hemolytic anemia | KG + DL |
| 16 | cold agglutinin disease | KG + DL |
| 17 | paroxysmal nocturnal hemoglobinuria | KG + DL |
| 18 | Glanzmann thrombasthenia | KG + DL |
| 19 | constitutional megaloblastic anemia due to folate metabolism disorder | KG + DL |
| 20 | esophageal disease | KG + DL |
| 21 | infantile digital fibromatosis | KG + DL |
| 22 | cerebral folate deficiency | KG + DL |
| 23 | inborn disorder of pyridoxine metabolism | KG + DL |
| 24 | acquired amyloid peripheral neuropathy | KG + DL |
| 25 | Ledderhose disease | KG + DL |
| 26 | C1 inhibitor deficiency | KG + DL |
| 27 | primary amyloidosis | KG + DL |
| 28 | penile fibromatosis | KG + DL |
| 29 | palmar fibromatosis | KG + DL |
| 30 | dermis disease | KG + DL |
| 31 | serpinopathy with toxic serpin polymerization | KG + DL |
| 32 | nodular cutaneous amyloidosis | KG + DL |
| 33 | amyloidosis cutis dyschromia | KG + DL |
| 34 | macular amyloidosis | KG + DL |
| 35 | amyloidosis (disease) | KG + DL |
| 36 | dermatomyositis | KG + DL |
| 37 | selective IgG immunodeficiency | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.